FDA Mumbai flags substandard drugs and skincare products in May 2026 crackdown

The Food and Drug Administration Laboratory in Mumbai identified several medicines and healthcare products as not of standard quality in May 2026. The findings were part of a broader national surveillance effort led by the Central Drugs Standard Control Organisation. A total of 159 drug samples across India failed quality tests during the same period. Among the products flagged by the Mumbai lab were Skeenglow Facewash and UV ETO SPF 50+ Sunscreen Lotion. Both failed microbial examination requirements set under Indian Standards.

An anti-allergy syrup, Levocetirizine Dihydrochloride Syrup, did not meet the manufacturer’s specifications for microbial contamination. Phytomenadione Injection BP also failed, as it did not meet the prescribed pH test under Indian Pharmacopoeia standards. Additionally, Ofloxacin and Ornidazole Tablets were found non-compliant with standards for related substances.

A drug sample from Assam was identified as a spurious product. It was manufactured by an unauthorised entity using a brand name owned by another company. The CDSCO continues to monitor and remove such substandard products from the market. The discoveries highlight ongoing issues with product quality in India’s pharmaceutical and healthcare sectors. Authorities remain active in identifying and addressing non-compliant items to protect public health. The CDSCO’s surveillance efforts are expected to continue as part of its regulatory duties.